Management of lung transplant recipients with bronchogenic carcinoma in the native lung

J Heart Lung Transplant. 2003 Jan;22(1):87-9. doi: 10.1016/s1053-2498(02)00446-1.


Experience with lung transplantation for bronchogenic carcinoma is limited. In our experience, 3 of 6 patients died of recurrent carcinoma within 5 to 35 months after transplantation. Hence, we currently do not support lung transplantation for patients with pre-transplant diagnosis of bronchogenic carcinoma, with the exception of bronchioloalveolar carcinoma (BAC) confined to the lung. Patients with BAC should be staged thoroughly with chest and abdominal computerized tomography, brain magnetic resonance imaging, and bone scan repeated every 3 months while on the waiting list, and should undergo mediastinoscopy at the time of transplantation, with a plan for a backup recipient if metastatic lymph nodes are detected. Proposal for lung transplantation for patients with bronchogenic carcinoma, with the exception of BAC, probably should be performed in the setting of a clinical trial developed with input from the lung transplant community.

MeSH terms

  • Carcinoma, Bronchogenic / mortality
  • Carcinoma, Bronchogenic / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery*
  • Lung Transplantation* / mortality
  • Male
  • Middle Aged
  • Time Factors